{"entity":{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","aka":[],"tldr":"Led the Chinese trials of PD-1 blockade in nasopharyngeal and lung cancer and the early studies of the EGFR×HER3 bispecific ADC iza-bren.","summary":"Li Zhang is Professor of Medical Oncology and Director of the Department of Medical Oncology at Sun Yat-sen University Cancer Center in Guangzhou. He led the Chinese trials of PD-1 blockade with camrelizumab and toripalimab in nasopharyngeal carcinoma and lung cancer, and the early-phase studies of izalontamab brengitecan, the EGFR and HER3 bispecific antibody-drug conjugate from SystImmune and Sichuan Biokin, in non-small-cell lung cancer and nasopharyngeal carcinoma. His publications include the CAPTAIN-1st trial of camrelizumab added to gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. His interests are lung cancer, nasopharyngeal carcinoma, immunotherapy and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20L%5BAuthor%5D%20Sun%20Yat-sen%20lung%20cancer%20camrelizumab"}],"tags":[],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["izalontamab-brengitecan","camrelizumab","toripalimab"],"companies":["systimmune"],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Director, Department of Medical Oncology, Sun Yat-sen University Cancer Center","institutionId":"sysucc","specialisms":["Lung cancer","Nasopharyngeal carcinoma","Immunotherapy","Antibody-drug conjugates"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20L%5BAuthor%5D%20Sun%20Yat-sen%20lung%20cancer%20camrelizumab"}],"papers":[{"title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00302-8"}]},"route":"/people/zhang-li-sysucc/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}],"institution":[{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/"}],"trial":[{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/"}]}}